Sumatriptan Causes Parallel Decrease in Plasma Calcitonin Gene-Related Peptide (CGRP) Concentration and Migraine Headache During Nitroglycerin Induced Migraine Attack

@article{Juhsz2005SumatriptanCP,
  title={Sumatriptan Causes Parallel Decrease in Plasma Calcitonin Gene-Related Peptide (CGRP) Concentration and Migraine Headache During Nitroglycerin Induced Migraine Attack},
  author={Gabriella Juh{\'a}sz and Ter{\'e}zia Zsomb{\'o}k and Bal{\'a}zs Jakab and J{\'o}zsef N{\'e}meth and J{\'a}nos Szolcs{\'a}nyi and Gyorgy Bagdy},
  journal={Cephalalgia},
  year={2005},
  volume={25},
  pages={179 - 183}
}
Sumatriptan-induced changes in plasma calcitonin gene-related peptide (CGRP) concentration and headache intensity were investigated in 19 female migraineurs during nitroglycerin-induced migraine attack. Sumatriptan nasal spray was administered 120 min after the onset of the attack. Blood samples were obtained immediately before and 60 min after sumatriptan administration. In those subjects whose migraine attack improved considerably 60 min after the treatment the plasma CGRP concentration… 

Tables from this paper

Sumatriptan Causes Parallel Decrease in Plasma CGRP Concentration and Migraine Headache During Nitroglycerin-Induced Migraine Attack
TLDR
This study concluded that triptans inhibit CGRP release, most likely by presynaptic inhibition of perivascular trigeminal nerves, and that this mechanism is, at least partially, responsible for the antimigraine efficacy of triptan.
Sumatriptan Causes Parallel Decrease in Plasma CGRP Concentration and Migraine Headache During Nitroglycerin-Induced Migraine Attack: Reply
TLDR
This study concluded that triptans inhibit CGRP release, most likely by presynaptic inhibition of perivascular trigeminal nerves, and that this mechanism is, at least partially, responsible for the antimigraine efficacy of triptan.
Sumatriptan does not change calcitonin gene-related peptide in the cephalic and extracephalic circulation in healthy volunteers
TLDR
It was found that Sumatriptan did not change the levels of circulating C GRP in the intra or extracerebral circulation in healthy volunteers, speaking against a direct CGRP-reducing effect of sumatripta in vivo in humans when the trigemino vascular system is not activated.
Calcitonin gene-related peptide (CGRP) levels during glyceryl trinitrate (GTN)-induced headache in healthy volunteers
TLDR
The NO donor GTN appears not to induce headache via immediate CGRP release, and there were no changes in VIP-, NPY- or somatostatin-LI.
Calcitonin gene-related peptide in blood: is it increased in the external jugular vein during migraine and cluster headache? A review
TLDR
It remains an enigma how the observed increase of CGRP in the EJV fits into the mechanisms of migraine and cluster headache.
Plasma calcitonin gene-related peptide concentration is comparable to control group among migraineurs and tension type headache subjects during inter-ictal period
TLDR
It is suggested that migraine and TTH could be episodic disorders and subjects have comparable CGRP levels during inter-ictal period.
Calcitonin gene-related peptide in peripheral blood as a biomarker for migraine
TLDR
It seems that peripheral CGRP levels are a good biomarker of acute migraine and somewhat specific and sensitive interictally in chronic migraine.
Dilation by CGRP of middle meningeal artery and reversal by sumatriptan in normal volunteers
TLDR
It is suggested that exogenous CGRP dilates extracranial vessels and not intracranial, and that sumatriptan exerts part of its antinociceptive action by constricting MMA and not MCA.
Novel migraine therapy with calcitonin gene-regulated peptide receptor antagonists
  • L. Edvinsson
  • Biology, Medicine
    Expert opinion on therapeutic targets
  • 2007
TLDR
The role of CGRP in human cranial circulation is described and the role for specific C GRP antagonism elucidated, and it is well known that triptans (5-HT1B/1D agonist) alleviate headache in part through normalisation of CgrP levels.
Ghrelin attenuated hyperalgesia induced by chronic nitroglycerin: CGRP and TRPV1 as targets for migraine management
TLDR
These results provide the first convincing evidence that ghrelin has a modulating effect on central sensitization induced by chronic intermittent nitroglycerin, and its antinociceptive effect may be related to a reduction of these factors in the trigeminal ganglion.
...
...

References

SHOWING 1-10 OF 32 REFERENCES
[Suppressing effect of the serotonin 5HT1B/D receptor agonist rizatriptan on calcitonin gene-related peptide (CGRP) concentration in migraine attacks].
TLDR
The results suggest that triptans as serotonin 5HT1B/D receptor agonists decrease CGRP plasma concentration in migraine attacks.
Cgrp May Play A Causative Role in Migraine
TLDR
It is suggested that the increase in CGRP observed during spontaneous migraine attacks may play a causative role and cause headache and migraine in migraineurs.
Headache Induced by a Nitric Oxide Donor (nitroglycerin) Responds to Sumatriptan. A Human Model for Development of Migraine Drugs
TLDR
NTG headache in non-migraineurs may share mechanisms with migraine headache, and the NTG model may prove to be a valuable tool in the development of future migraine drugs.
The Pharmacodynamics of Sumatriptan in Nitroglycerin‐Induced Headache
TLDR
The results suggest that NTG‐induced headache and the development of pharmacokinetic/pharmacodynamic models could serve as a useful method for exploring the mechanisms of abortive migraine drugs.
Regulation of Calcitonin Gene-Related Peptide Secretion by a Serotonergic Antimigraine Drug
TLDR
The results suggest that 5-HT1 agonists may block a deleterious feedback loop in migraine at the trigeminal neurons and provide a general mechanism by which this class of drugs can attenuate stimulated neuropeptide release.
Blockade of calcitonin gene-related peptide release after superior sagittal sinus stimulation in cat: a comparison of avitriptan and CP122,288
TLDR
It is demonstrated that the potent inhibitor of PPE, CP122, 288, which has been shown in clinical trials to be ineffective in treating acute migraine attacks, had no effect on CGRP release, whereas the effective anti-migraine drug and relatively impotent inhibitor ofPPE, avitriptan, blocked C GRP release.
Calcitonin Gene-Related Peptide (CGRP) and the Pathophysiology of Headache
TLDR
The central role of CGRP in primary headaches has led to the search for suitable antagonists of the receptors for this neuropeptide, which it is hoped will have less cardiovascular adverse effects than the triptans.
Nitric oxide synthase inhibitors can antagonize neurogenic and calcitonin gene‐related peptide induced dilation of dural meningeal vessels
TLDR
Data suggest that the delayed headache response triggered by NO donors in humans may be due, in part, to increased nNOS activity in the trigeminal system that causes CGRP release and dural vessel dilation, and may be involved in the initial headache response.
...
...